日报更新时间：
周报更新时间：01-23 11:54
今开价：
最高价：
成交量：
昨收价：
最低价：
最新价：
英文名称：Cormedix
简介：Cormedix Inc.是于2006年7月28日在美国特拉华州注册成立
电话：1-908-5179500
CorMedix Inc.是一家生物制药公司，致力于开发和商业化用于预防和治疗传染病和炎症性疾病的治疗产品。CorMedix公司致力于开发其主要产品Neutrolin®，这是一种新型非抗生素抗菌解决方案，旨在预防与中心静脉导管相关的昂贵且危险的血流感染，目前正在进行 III 期临床试验，招募接受慢性血液透析的患者。这种感染每年花费美国医疗保健系统大约60亿美元，并且显着增加了发病率和死亡率。Neutrolin具有FDA快速通道，被指定为合格的传染病产品，可提供FDA优先审核的潜力，如果获得在美国批准销售，将获得五年的QIDP市场独占（专利保护）。Neutrolin®已经在欧洲和其他地方上市。与此同时，CorMedix正在利用其taurolidine（牛磺罗定）技术开发出一系列抗菌医疗设备，其中包括手术缝合线和网状物以及局部水凝胶的活跃程序。此外，CorMedix公司还与顶级研究人员合作，为罕见的儿科癌症开发基于taurolidine的疗法。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2019-07-11 | Dunton (Alan W) | Director | Buy | 1250 | -- |
| 2019-05-14 | Dillione (Janet M) | Director | Buy | 11144 | 6.74 |
| 2019-03-28 | Cook (Robert W.) | Chief Financial Officer | Buy | 100 | 9.35 |
| 2019-03-25 | Armstrong (John L Jr) | Officer | Buy | 5000 | 7.73 |
| 2019-03-25 | Baluch (Khoso) | Chief Executive Officer | Buy | 2500 | 7.55 |
| 2019-03-24 | Armstrong (John L Jr) | Officer | Buy | 15000 | 1.69 |
| 2019-03-17 | Dillione (Janet M) | Director | Buy | 42000 | 1.67 |
| 2018-12-30 | Armstrong (John L Jr) | Officer | Buy | 18029 | -- |
| 2018-12-19 | Lefkowitz (Steven W) | Director | Buy | 20000 | 1.18 |
| 2018-12-19 | Khan (Mehmood) | Director | Buy | 100000 | 1.24 |
| 2018-12-13 | Kaplan (Myron) | Director | Buy | 50000 | 1.47 |
| 2018-12-04 | Masson (Elizabeth) | Officer | Buy | 40000 | 0.29 |
| 2018-11-28 | Armstrong (John L Jr) | Officer | Buy | 250000 | 1.45 |
| 2018-11-26 | Baluch (Khoso) | Chief Executive Officer | Buy | 21500 | 1.21 |
| 2018-11-26 | Cook (Robert W.) | Chief Financial Officer | Buy | 25000 | 1.17 |
| 2018-11-25 | Baluch (Khoso) | Chief Executive Officer | Buy | 3500 | 1.28 |
| 2018-11-22 | Kaplan (Myron) | Director | Buy | 50000 | 1.30 |
| 2018-11-05 | Kaplan (Myron) | Director | Buy | 5000 | -- |
| 2018-10-11 | GELBFISH GARY A | Director | Sell | 468750 | 2.24 |
| 2018-10-11 | GELBFISH GARY A | Director | Buy | 1000000 | 1.05 |
| 2018-09-30 | Lefkowitz (Steven W) | Director | Buy | 10000 | -- |
| 2018-02-20 | Kaplan (Myron) | Director | Buy | 10000 | -- |
| 2018-02-20 | Dillione (Janet M) | Director | Buy | 15357 | -- |
| 2018-02-15 | Khan (Mehmood) | Director | Buy | 12500 | -- |
| 2018-02-15 | GELBFISH GARY A | Director | Buy | 10000 | -- |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Northern Trust Investments N A | 44628 | 0.19% | -999 | -2.19% | 2019-03-31 |
| Geode Capital Management, LLC | 157773 | 0.66% | 157773 | -- | 2019-03-31 |
| Fidelity Management & Research Company | 162759 | 0.68% | 11069 | 7.30% | 2019-07-31 |
| Millennium Management LLC | 230923 | 0.97% | 225125 | 3882.80% | 2019-03-31 |
| BlackRock Inc | 421602 | 1.77% | -109732 | -20.65% | 2019-03-31 |
| Vanguard Investments Australia Ltd | 573586 | 2.41% | -- | -- | 2019-07-31 |
| BlackRock Fund Advisors | 809430 | 3.40% | 1012 | 0.13% | 2019-07-31 |
| Elliott Management Corp | 833373 | 3.50% | -1 | -- | 2019-03-31 |
| Vanguard Group Inc | 921422 | 3.87% | 93678 | 11.32% | 2019-03-31 |
| EAM Investors, LLC | 146472 | 0.62% | 27587 | 23.20% | 2019-03-31 |
| Goldman Sachs Group Inc | 123695 | 0.52% | 123695 | -- | 2019-03-31 |
| BlackRock | 106701 | 0.45% | 61398 | 135.53% | 2019-07-31 |
| Northern Trust Corp | 44628 | 0.19% | -999 | -2.19% | 2019-03-31 |
| BlueCrest Capital Management Ltd. | 45231 | 0.19% | 45231 | -- | 2019-03-31 |
| Tibra Equities Europe Ltd | 62791 | 0.26% | 62791 | -- | 2019-03-31 |
| BlackRock Institutional Trust Company NA | 63136 | 0.27% | 63136 | -- | 2019-07-31 |
| Bridgeway Capital Management, Inc | 68500 | 0.29% | 68500 | -- | 2019-03-31 |
| Spinnaker Capital LLC | 80384 | 0.34% | -- | -- | 2019-03-31 |
| Northern Trust Investments Inc | 85690 | 0.36% | 29997 | 53.86% | 2019-07-31 |
| EAM Global Investors, LLC | 99437 | 0.42% | 99437 | -- | 2019-03-31 |
| Bank of America Corporation | 42881 | 0.18% | 41856 | 4083.51% | 2019-03-31 |
| Catalyst Capital Advisors LLC | 40800 | 0.17% | 40800 | -- | 2019-03-31 |
| Franklin Resources Inc | 37894 | 0.16% | 2235 | 6.27% | 2019-03-31 |
| Steward Partners Investment Advisory, LLC | 38278 | 0.16% | 22500 | 142.60% | 2019-03-31 |
| BlackRock Advisors (UK) Ltd | 31884 | 0.13% | 31884 | -- | 2019-03-31 |
| Barclays PLC | 31998 | 0.13% | 31998 | -- | 2019-03-31 |
| K2/D&S Management Co., L.L.C. | 178295 | 0.15% | 7827 | 4.59% | 2018-12-31 |
| Bank of New York Mellon Corp | 150689 | 0.13% | 113029 | 300.13% | 2018-12-31 |
| Mellon Investments Corporation | 21943 | 0.09% | 3176 | 16.92% | 2019-04-30 |
| Principal Global Investors, LLC | 26371 | 0.11% | 26371 | -- | 2019-04-30 |
| BNY Mellon Investment Management | 150689 | 0.13% | 113029 | 300.13% | 2018-12-31 |
| Group One Trading, LP | 78135 | 0.07% | 77389 | 10373.86% | 2018-12-31 |
| Wells Fargo & Co | 105842 | 0.09% | 105842 | -- | 2018-12-31 |
| Planning Directions Inc | 107409 | 0.09% | -- | -- | 2018-12-31 |
| Private Advisor Group, LLC | 73034 | 0.06% | 1294 | 1.80% | 2018-12-31 |
| State Street Corporation | 68247 | 0.06% | 53500 | 362.79% | 2018-12-31 |
| Virtu Financial LLC | 394051 | 0.37% | 206099 | 109.66% | 2018-09-30 |
| Susquehanna Financial Group, LLLP | 73582 | 0.07% | 73582 | -- | 2018-09-30 |
| Susquehanna International Group, LLP | 73582 | 0.07% | 73582 | -- | 2018-09-30 |
| Atlantic Trust Group, LLC | 60000 | 0.06% | 30000 | 100.00% | 2018-09-30 |
| HighTower Advisors, LLC | 48188 | 0.04% | 1000 | 2.12% | 2018-09-30 |
| Analytic Investors, LLC | 41346 | 0.04% | 41346 | -- | 2019-01-31 |
| Franklin Advisers, Inc. | 170468 | 0.16% | -52786 | -23.64% | 2018-09-30 |
| Citadel Advisors Llc | 41661 | 0.04% | -211158 | -83.52% | 2018-06-30 |
| The Variable Annuity Life Insurance Company | 40000 | 0.04% | -- | -- | 2018-10-31 |
| Sabby Management LLC | 3344568 | 4.68% | -1788764 | -34.85% | 2017-12-31 |
| Elliott Associates LP | 1333398 | 1.99% | 1333398 | -- | 2017-11-09 |
| Franklin Advisers Inc | 223254 | 0.26% | 15891 | 7.66% | 2018-06-30 |
| TWO SIGMA SECURITIES, LLC | 78819 | 0.09% | 78819 | -- | 2018-03-31 |
| Taurus Asset Management, LLC | 30000 | 0.03% | -- | -- | 2018-06-30 |
| Washington Trust Co | 24750 | 0.03% | -- | -- | 2018-03-31 |
| State Street Corp | 17767 | 0.02% | -- | -- | 2018-06-30 |
| Morgan Stanley Smith Barney LLC | 14000 | 0.01% | -- | -- | 2018-06-30 |
| UBS Securities LLC | 28700 | 0.03% | -34254 | -54.41% | 2018-03-31 |
| Commonwealth Equity Services Inc | 16386 | 0.02% | -- | -- | 2017-12-31 |
| Brandes Investment Partners & Co | 85000 | 0.12% | 85000 | -- | 2017-12-31 |
| Bt Alex Brown Inc | 51600 | 0.07% | 51600 | -- | 2017-12-31 |
| Merrill Lynch & Co Inc | 32000 | 0.04% | 5000 | 18.52% | 2017-12-31 |
| Mellon Capital Management Corporation | 24944 | 0.04% | 24944 | -- | 2017-12-31 |
| Nine Chapters Capital Management LLC | 42400 | 0.07% | 42400 | -- | 2017-09-30 |
| Ray Gerald L & Associates Ltd | 57000 | 0.09% | -70000 | -55.12% | 2017-09-30 |
| Bollard Group LLC | 401920 | 0.65% | -- | -- | 2017-09-30 |
| Hudson Bay Capital Management LP | 791632 | 1.33% | 791632 | -- | 2017-06-30 |
| Spot Trading LLC | 69600 | 0.17% | 69600 | -- | 2016-09-30 |
| Goldman, Sachs & Co. | 78817 | 0.20% | 4425 | 5.95% | 2016-09-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| NT Ext Equity Market Index Fund - L | 20635 | 0.09% | -- | -- | 2019-06-30 |
| Fidelity | 45353 | 0.19% | 11069 | 32.29% | 2019-06-30 |
| Schwab Small Cap Index Fund | 49061 | 0.21% | 49061 | -- | 2019-06-30 |
| iShares Micro-Cap ETF | 59881 | 0.25% | -- | -- | 2019-07-30 |
| Bridgeway Ultra Small Company Market Fd | 66000 | 0.28% | 66000 | -- | 2019-03-31 |
| iShares Russell 2000 Growth ETF | 213616 | 0.90% | -- | -- | 2019-07-30 |
| Vanguard Extended Market Index Fund | 333721 | 1.40% | 783 | 0.24% | 2019-06-30 |
| iShares Russell 2000 ETF | 514264 | 2.16% | 1012 | 0.20% | 2019-07-30 |
| Vanguard Total Stock Market Index Fund | 573586 | 2.41% | -- | -- | 2019-06-30 |
| BlackRock Extended Equity Market | 45242 | 0.19% | -61 | -0.13% | 2019-06-30 |
| Catalyst Small Cap Insider Buying Fund | 40800 | 0.17% | 40800 | -- | 2019-03-31 |
| Vanguard Russell 2000 Index Fund | 21369 | 0.09% | 21369 | -- | 2019-06-30 |
| BlackRock Russell 2000 | 22979 | 0.10% | 22979 | -- | 2019-06-30 |
| BlackRock Russell 2500 | 23913 | 0.10% | 23913 | -- | 2019-06-30 |
| Vanguard Instl Total Stock Market Idx Fd | 25705 | 0.11% | -- | -- | 2019-06-30 |
| iShares Russell 2000 Small-Cap Index Fd | 26390 | 0.11% | 26390 | -- | 2019-06-30 |
| LVIP SSgA Small Cap Index Fund | 29200 | 0.12% | 29200 | -- | 2019-06-30 |
| The Vanguard - Russell 2000 Grwth Idx CF | 33163 | 0.14% | 33163 | -- | 2019-06-30 |
| Russell 2000 Index Non-Lendable Fund E | 34748 | 0.15% | 34748 | -- | 2019-06-30 |
| Mandarine Global Microcap | 20000 | 0.08% | 20000 | -- | 2019-03-31 |
| NT Extended Equity Market Idx Fund - NL | 18899 | 0.08% | -- | -- | 2019-06-30 |
| Principal Healthcare Innovators ETF | 18285 | 0.08% | -- | -- | 2019-06-30 |
| BNYM Mellon NSL Mkt Completion Fd Instl | 16966 | 0.07% | 15720 | 1261.64% | 2019-03-31 |
| Northern Small Cap Core Fund | 15200 | 0.06% | 15200 | -- | 2019-06-30 |
| Vanguard Balanced Index Fund | 14815 | 0.06% | -- | -- | 2019-05-31 |
| NT Ext Equity Mkt Fd - DC - NL | 12539 | 0.05% | -221 | -1.73% | 2019-03-31 |
| SPDR | 12635 | 0.05% | -- | -- | 2019-06-28 |
| State Street U.S. Extended Market Index | 13508 | 0.06% | -- | -- | 2019-05-31 |
| Principal US Small Cap Mlt Fac Ind ETF | 8086 | 0.03% | -- | -- | 2019-05-31 |
| Wells Fargo Factor Enhanced Sm Cp IdxCIT | 7031 | 0.03% | -1239 | -14.98% | 2019-03-31 |
| Schwab Total Stock Market Index Fund | 5920 | 0.02% | -- | -- | 2019-05-31 |
| iShares Core S&P Total US Stock Mkt ETF | 5248 | 0.02% | 13 | 0.25% | 2019-06-26 |
| NT Ext Equity Mkt Idx Fd - DC - NL | 12539 | 0.05% | -221 | -1.73% | 2019-03-31 |
| iShares Core S&P US Total Market ETF | 5038 | 0.02% | -- | -- | 2019-05-30 |
| Vanguard US Equity Index Fund | 4880 | 0.02% | -- | -- | 2019-04-30 |
| BNYM Mellon SL Mkt Completion Fd | 4977 | 0.02% | -12544 | -71.59% | 2019-03-31 |
| USAA Extended Market Index Fund | 7588 | 0.01% | -- | -- | 2019-01-31 |
| NT US Market Cap Index Fund - Lending | 3358 | 0.01% | -947 | -22.00% | 2019-03-31 |
| Wells Fargo Factor Enhanced Small Cap | 16947 | 0.01% | -5891 | -25.79% | 2019-01-31 |
| The Vanguard Total Stock Market Index | 3798 | 0.02% | 3798 | -- | 2019-03-31 |
| Spartan Total Market Index Pool | 19417 | 0.02% | 19417 | -- | 2019-01-31 |
| Wells Fargo Factor Enhanced Small Cp Fd | 52 | -- | -8 | -13.33% | 2019-01-31 |
| Esfera III Titan Dynamic FI | 2000 | -- | -1000 | -33.33% | 2019-02-28 |
| BNY Mellon Market Completion Fund | 6231 | 0.01% | -4940 | -44.22% | 2018-12-31 |
| VALIC Company I Small Cap Fund | -- | -- | -40000 | -100.00% | 2018-03-31 |
| Master Extended Market Index Series | -- | -- | -7588 | -100.00% | 2018-02-28 |
| Vanguard Total Stock Mkt Idx | 1253757 | 1.47% | -- | -- | 2018-07-31 |
| Vanguard Extended Market Idx Inv | 419187 | 0.49% | 19400 | 4.85% | 2018-07-31 |
| Vanguard Balanced Index Inv | 87680 | 0.10% | -- | -- | 2018-07-31 |
| Fidelity Spartan | 48587 | 0.06% | -- | -- | 2018-07-31 |
| BlackRock Extended Equity Market K | 77669 | 0.09% | 2112 | 2.80% | 2018-06-30 |
| Vanguard Instl Ttl Stk Mkt Idx InstlPls | 23800 | 0.03% | -- | -- | 2018-07-31 |
| iShares Core S&P Total US Stock Mkt | 19015 | 0.02% | -- | -- | 2018-09-12 |
| BNY Mellon EB DL Mkt Completion | 34707 | 0.04% | -- | -- | 2018-06-30 |
| USAA Extended Market Index | 7588 | 0.01% | -- | -- | 2018-07-31 |
| BNY Mellon Market Completion Fund UC1 | 11171 | 0.01% | 9614 | 617.47% | 2018-03-31 |
| SSgA U.S. Total Market Index Fd Class I | 3920 | 0.01% | -256 | -6.13% | 2017-12-31 |
| VALIC Company I Small Cap | 40000 | 0.06% | -- | -- | 2018-02-28 |
| Bridgeway Ultra-Small Company Market | 127701 | 0.18% | -50000 | -28.14% | 2017-12-31 |
| iShares Micro-Cap | 97409 | 0.30% | -- | -- | 2017-02-07 |
| AXA/Lord Abbett Micro Cap K | 6317 | 0.02% | -- | -- | 2016-11-30 |
| State Street Russell Small Cap Growth Idx Cl A | 2600 | 0.01% | -- | -- | 2015-12-31 |
| Marketocracy Masters 100 | 1600 | -- | -- | -- | 2016-12-31 |
| BlackRock LifePath | 27 | -- | 9 | 50.00% | 2016-03-31 |
| iShares Russell 2000 Growth | 271676 | 0.80% | -- | -- | 2015-11-27 |
| Bridgeway Ultra Small Company Market | 168001 | 0.50% | 113001 | 205.50% | 2015-09-30 |
| Fidelity Spartan® Extended Mkt Indx Fd | 116216 | 0.30% | -- | -- | 2015-10-31 |
| CREF Stock Account | 75434 | 0.20% | -- | -- | 2015-09-30 |
| AQR Small Cap Momentum Style Fund | 71090 | 0.20% | -- | -- | 2015-09-30 |
| Northern Trust Russell 2000 Index Fund - DC - Non-Lending | 65842 | 0.20% | -2900 | -4.20% | 2015-09-30 |
| AXA 2000 Managed Volatility Portfolio | 48639 | 0.10% | 7502 | 18.20% | 2015-09-30 |
| Fidelity Spartan® Total Market Idx Fund | 48587 | 0.10% | -- | -- | 2015-10-31 |
| BlackRock Russell 2000® Index Non-Lendable Fund | 45653 | 0.10% | 14234 | 45.30% | 2015-09-30 |
| Schwab Small Cap Index Fund® | 45377 | 0.10% | -- | -- | 2015-09-30 |
| iShares Russell 2000 (AU) | 555178 | 1.50% | -339 | -0.10% | 2015-11-27 |
| Myron Kaplan | Currently, Myron Kaplan is Chairman for CorMedix, Inc. He is also on the board of JBI International, Inc. and Founding Partner of Kleinberg, Kaplan, Wolff & Cohen PC. Mr. Kaplan received an undergraduate degree from Columbia College Corp. and a graduate degree from Harvard Law School. |
|---|---|
| John L. Armstrong | Presently, John L. Armstrong is EVP-Technical Operations & Head-Human Resources at CorMedix, Inc. Mr. Armstrong previously was President & Chief Executive Officer for Genaera Corp., President & Chief Operating Officer for Oread, Inc., President-Operations at Correvio LLC, Chief Executive Officer of Mills Biopharmaceuticals LLC, President-ENDO Laboratories at DuPont Merck Pharmaceutical Co., Vice President-Operation at Marion Merrell Dow, Inc. and Senior Vice President-Business Development for UroCor, Inc. John L. Armstrong received an MBA from Century College and an undergraduate degree from Juniata College. |
| Steven W. Lefkowitz | Founder of Wade Capital Corp., Steven W. Lefkowitz is on the board of CorMedix, Inc., AIS RE Ltd. and Specialty Liquid Transportation Corp. In his past career he was President of Wade Capital Corp., Director at CorMedix, Inc., Vice President-Corporate Finance at Drexel Burnham Lambert, Inc. and Chairman of MEDCONX, Inc. Mr. Lefkowitz received an undergraduate degree from Dartmouth College and an MBA from Columbia Business School. |
| Mehmood A. Khan | Mehmood A. Khan holds the position of Chief Executive Officer & Director at Life Biosciences LLC. He is also on the board of CorMedix, Inc., HemoShear LLC, Reckitt Benckiser Group Plc and Indigo Agriculture, Inc. and Fellow at American College of Endocrinology and Member of The Royal College of Physicians. He previously was Vice Chairman & CSO-Global Research & Development at PepsiCo, Inc., President at Takeda Global Research & Development Center, Inc., Chief Medical Officer at Takeda Pharmaceuticals U.S.A., Inc., Director-Diabetes & Endocrinology at The Mayo Clinic (Old) and Member of Mayo Medical School. Dr. Khan received a doctorate from The University of Liverpool. |
| Robert W. Cook | Currently, Robert W. Cook is Chief Financial Officer for CorMedix, Inc. Mr. Cook previously was Chief Financial Officer & Executive Vice President for Pharmos Corp., Chief Financial Officer, Secretary & Treasurer for STRATA Skin Sciences, Inc., Chief Financial Officer, Director & Senior VP at Immune Pharmaceuticals, Inc. and President, CEO, CFO, Secretary & Director at EpiCept Corp. (a subsidiary of Immune Pharmaceuticals, Inc.), Managing Director at The Chase Manhattan Bank NA, Chief Financial Officer at Bioblast Pharma Ltd. and Vice President-Healthcare Group at GE Capital Commercial Finance, Inc. Robert W. Cook received an undergraduate degree from American University. |
| Alan W. Dunton | Alan W. Dunton is a businessperson who founded Danerius LLC and who has been at the helm of 6 different companies. Currently, Dr. Dunton is Senior Vice President-Research & Development at Purdue Pharmaceuticals LP. He is also on the board of Palatin Technologies, Inc., Oragenics, Inc., CorMedix, Inc. and Cytogel Pharma LLC. In his past career he held the position of Chairman at Janssen Cilag International NV, President & Chief Executive Officer for Panacos Pharmaceuticals, Inc., President, Chief Operating Officer & Director at Emisphere Technologies, Inc., Head-Research & Development at Purdue Pharma LP, Chief Medical Officer for Adhera Therapeutics, Inc., Principal at Danerius LLC, Senior Executive at Johnson & Johnson President & Managing Director at The Janssen Research Foundation, VP-Global Clinical Research & Development at R.W. Johnson Pharmaceutical Research Institute and Member-Group Operating Committee at Johnson & Johnson Pharmaceutical Group (which are all subsidiaries of Johnson & Johnson), Non-Executive Chairman of EpiCept Corp., President & Chief Executive Officer for Metaphore Pharmaceuticals, Inc., Chief Medical Officer for Derma Sciences, Inc., Vice President-Clinical Research & Development at Syntex Corp., Vice President-Clinical Research & Development at Ciba-Geigy Corp. and Vice President-Clinical Research & Development at Hoffmann-La Roche, Inc. Alan W. Dunton received a doctorate from New York University School of Medicine and an undergraduate degree from State University of New York at Buffalo. |
| Andrew Robert John Bonfield | Currently, Andrew Robert John Bonfield is Chairman of The Hundred Group of Finance Directors and Chief Financial Officer of Caterpillar, Inc. He is also on the board of Reckitt Benckiser Group Plc, National Grid Holdings One Plc and National Grid Holdings Ltd. In his past career Mr. Bonfield occupied the position of Executive Director & Finance Director at National Grid Plc, Chief Financial Officer & Executive Vice President of Bristol-Myers Squibb Co., Chief Financial Officer of Smithkline Beecham Plc, Finance Director of BG Group Ltd. and Chief Financial Officer for Cadbury Ltd. Andrew Robert John Bonfield received an undergraduate degree from University of Natal. |
| Antony E. Pfaffle | Founder of CorMedix, Inc. and Black Diamond Research LLC, Antony E. Pfaffle holds the position of Secretary & Chief Scientific Officer at CorMedix, Inc. In his past career Dr. Pfaffle was Director-Healthcare Research at Bearing Circle Capital LP, Principal at Black Diamond Research LLC, Managing Director at Paramount BioCapital, Inc. and Senior Vice President-Business Development of Paramount BioSciences LLC (a subsidiary of Paramount BioCapital, Inc.), Analyst at BDR Research LLC, Medical Director at ParagonRx International LLC, Consultant at Memorial Sloan-Kettering Cancer Center and Faculty Member at New York University. Antony E. Pfaffle received a doctorate from New York Medical College. |
| Janet D. Dillione | Currently, Janet D. Dillione is Chief Executive Officer of Bernoulli Enterprise, Inc. Ms. Dillione is also on the board of CorMedix, Inc. In the past she held the position of Executive Vice President & GM-Healthcare Division at Nuance Communications, Inc., Chief Executive Officer at Cardiopulmonary Corp. and President & CEO-Global Healthcare IT Division at Siemens Medical Solutions USA, Inc. Ms. Dillione received an undergraduate degree from Brown University. |
| Mehmood A. Khan | Mehmood A. Khan holds the position of Chief Executive Officer & Director at Life Biosciences LLC. He is also on the board of CorMedix, Inc., HemoShear LLC, Reckitt Benckiser Group Plc and Indigo Agriculture, Inc. and Fellow at American College of Endocrinology and Member of The Royal College of Physicians. He previously was Vice Chairman & CSO-Global Research & Development at PepsiCo, Inc., President at Takeda Global Research & Development Center, Inc., Chief Medical Officer at Takeda Pharmaceuticals U.S.A., Inc., Director-Diabetes & Endocrinology at The Mayo Clinic (Old) and Member of Mayo Medical School. Dr. Khan received a doctorate from The University of Liverpool. |
| Mohammed Khoso Baluch | Currently, Mohammed Khoso Baluch holds the position of Chief Executive Officer & Director at CorMedix, Inc. He is also on the board of Poxel SA. In the past he was Chairman at Ucb Pharma Sp zoo, Manager for UCB Pharma SA, Senior VP & President-EMEA Region at UCB SA Director & Senior Vice President at UCB, Inc. and Manager of Vedim Pharma SA (both are subsidiaries of UCB SA), Principal at Eli Lilly & Co., Chairman of UCB Pharma AB and Chairman at Ucb Pharma AS. He received an undergraduate degree from City University London and an MBA from Cranfield University. |
| John Ortiz | John Ortiz holds the position of VP-Regulatory Affairs & Quality Assurance at CorMedix, Inc. In his past career Mr. Ortiz occupied the position of Head-Quality Assurance & Regulatory Affairs at Johnson & Johnson, Inc., Head-Quality Assurance & Regulatory Affairs at Correvio LLC and Head-Quality Assurance & Regulatory Affairs at Janssen Pharmaceuticals, Inc. |
| Robert W. Cook | Currently, Robert W. Cook is Chief Financial Officer for CorMedix, Inc. Mr. Cook previously was Chief Financial Officer & Executive Vice President for Pharmos Corp., Chief Financial Officer, Secretary & Treasurer for STRATA Skin Sciences, Inc., Chief Financial Officer, Director & Senior VP at Immune Pharmaceuticals, Inc. and President, CEO, CFO, Secretary & Director at EpiCept Corp. (a subsidiary of Immune Pharmaceuticals, Inc.), Managing Director at The Chase Manhattan Bank NA, Chief Financial Officer at Bioblast Pharma Ltd. and Vice President-Healthcare Group at GE Capital Commercial Finance, Inc. Robert W. Cook received an undergraduate degree from American University. |
| Elizabeth Masson | Elizabeth Masson is Executive Vice President& Head-Clinical Operations at CorMedix, Inc. In her past career she was Vice President-Clinical Operations at Gemphire Therapeutics, Inc. She received an undergraduate degree from Bay Path College. |
| Phoebe Mounts | Phoebe Mounts received a graduate degree from Georgetown University Law Center and a doctorate from The University of Edinburgh. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论